Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Cutting Edge Cannabinoid Cancer Treatment Enters Final Stage

Proactive Investors, www.proactiveinvestors.co.uk
1 Comment| April 30, 2019

{{labelSign}}  Favorites
{{errorMessage}}



PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, Forum) Chief Research Officer Dr Harry Parekh joined Steve Darling from Proactive Investors Vancouver to talk about the companies progress in the development of their sol-gel. Parekh telling proactive the next step they are undertaking with human tissue. He also talked about the progress made in screening peptides isolated from Caribbean Blue Scorpion venom to help combat some of the most aggressive diseases where there exists unmet clinical need, such as cancer.



{{labelSign}}  Favorites
{{errorMessage}}

Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today

Featured Company